THThe Hindu·3hBusiness
score-0.60
FDA Issues Warning Letter to Eugia Pharma Specialities Following Four Observations at Hyderabad Unit
Original
U.S. FDA issues warning letter to Aurobindo Pharma’s subsidiary Eugia Pharma
“Regulatory warnings and 'Official Action Indicated' status signal serious compliance failures, creating a negative tone regarding corporate reliability.”